Live Analyst Rating Changes 32921 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Boobalan Pachaiyappan
ROTH

Boobalan Pachaiyappan

Roth MKM
Wall Street Analyst
★★☆☆☆
#2645
on 13Foresight · ranked by our own returns
41%
Success Rate
-3.5%
Average Return
20 of 49 calls profitable · -124.7% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 41% of Boobalan Pachaiyappan's ratings turned a profit when each position was held for 1 year — averaging -3.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

98 Buy 5 Hold 0 Sell
Boobalan's Stock Coverage 26 ratings · 2026-09-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
ABEO
Abeona Therapeutics
 Sep 17, 2026 BUY Strong Buy
+207.9% avg upside
18 analysts
$17.00
205.16% Upside
 · ·
MNOV
Medicinova
 Sep 17, 2026 BUY Strong Buy
+114.3% avg upside
6 analysts
$6.00
80.68% Upside
 · ·
ANVS
Annovis Bio
 Sep 04, 2026 BUY Strong Buy
+1889.8% avg upside
8 analysts
$7.00
514.04% Upside
 -18.0% ·
OVID
Ovid Therapeutics
 Sep 03, 2026 BUY Strong Buy
+93.0% avg upside
18 analysts
$8.00
197.32% Upside
 -3.6% ·
IMUX
Immunic
 Sep 01, 2026 BUY Strong Buy
+267.8% avg upside
22 analysts
$29.00
173.04% Upside
 -21.7% ·
CAPR
Capricor Therapeutics
 Aug 25, 2026 HOLD Strong Buy
+207.3% avg upside
12 analysts
$7.00
22.69% Downside
 +1.0% ·
CING
Cingulate Inc
 Aug 24, 2026 BUY Strong Buy
+288.8% avg upside
5 analysts
$9.00
71.70% Upside
 -11.6% ·
COYA
Coya Therapeutics, Inc.
 Aug 23, 2026 BUY Strong Buy
+231.9% avg upside
7 analysts
$12.00
145.40% Upside
 -11.7% ·
PMN
ProMIS Neurosciences
 Aug 21, 2026 BUY Strong Buy
+378.4% avg upside
9 analysts
$29.00
106.95% Upside
 -6.6% ·
CRVO
CervoMed
 Aug 20, 2026 BUY Strong Buy
+637.2% avg upside
9 analysts
$7.00
188.05% Upside
 +0.4% ·
LGVN
Longeveron
 Aug 19, 2026 BUY Strong Buy
+1711.9% avg upside
4 analysts
$3.00
20.39% Upside
 -10.8% ·
GANX
Gain Therapeutics
 Aug 18, 2026 BUY Strong Buy
+343.9% avg upside
9 analysts
$8.00
354.54% Upside
 -13.3% ·
PYPD
PolyPid
 Aug 14, 2026 BUY Strong Buy
+205.9% avg upside
7 analysts
$8.00
53.49% Upside
 +8.9% ·
TRDA
Entrada Therapeutics Inc
 Aug 12, 2026 BUY Strong Buy
+213.1% avg upside
10 analysts
$11.00
63.03% Upside
 -10.3% ·
NRSN
Neurosense Therapeutics Ltd.
 Jun 10, 2026 BUY Strong Buy
+27.2% avg upside
5 analysts
$3.00
52.84% Downside
 · ·
LBRX
LB Pharmaceuticals, Inc.
 May 18, 2026 BUY Strong Buy
+24.4% avg upside
8 analysts
$37.00
12.87% Downside
 +60.9% ·
RVPH
Reviva Pharmaceuticals Holdings
 Apr 01, 2026 BUY Strong Buy
+8650.4% avg upside
9 analysts
$1.00
108.35% Upside
 -33.9% ·
BWAY
Brainsway
 May 20, 2024 HOLD Strong Buy
+5.0% avg upside
10 analysts
 — +94.7% ·
RKTO
Rocket One
 May 20, 2024 HOLD Strong Buy
+1278.2% avg upside
8 analysts
 — -29.5% ·
TSE:CSCI
COSCIENS Biopharma
 May 20, 2024 HOLD Strong Buy
+121.7% avg upside
8 analysts
 — · ·
ENSC
Ensysce Biosciences
 May 20, 2024 HOLD Buy
+3222.2% avg upside
3 analysts
 — · ·
PXMD
PaxMedica, Inc.
 May 20, 2024 HOLD Hold
1 analyst
 — · ·
ANEB
Anebulo Pharmaceuticals
 May 20, 2024 HOLD Buy
+1066.7% avg upside
5 analysts
 — -53.0% ·
SPRB
Spruce Biosciences
 May 20, 2024 HOLD Strong Buy
+94.7% avg upside
16 analysts
 — · ·
DMRA
Damora Therapeutics
 Oct 24, 2023 HOLD Strong Buy
+26.9% avg upside
20 analysts
 — -48.8% ·
OBX
Obsidian Therapeutics
 Sep 19, 2023 HOLD Strong Buy
-4.0% avg upside
11 analysts
$0.30
98.34% Downside
 · ·
🔒 21 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Boobalan Pachaiyappan — Frequently Asked Questions
How accurate are Boobalan Pachaiyappan's stock ratings?
Based on the calls 13Foresight could measure, about 41% of Boobalan's ratings were profitable over a one-year hold, with an average return of -3.5% per rating, or -124.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Boobalan ranked on 13Foresight?
Boobalan Pachaiyappan is currently ranked #2645 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Boobalan cover?
Boobalan most recently has ratings on ABEO, MNOV, ANVS, OVID, IMUX, CAPR, CING, COYA, PMN, CRVO, LGVN, GANX and 14 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.